Phase 1b Results of a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Obinutuzumab, ibrutinib, and venetoclax can be safely administered in combination at doses standard for the treatment of patients with CLL, with manageable adverse events that were largely consistent with those reported in single-agent studies. Objective responses, including minimal residual disease–negative responses, were observed among all patients with relapsed/refractory CLL.
Changes in Clinical Stage Identify Different Response Categories Among Patients in iwCLL PR: Analysis of CLL Patients on the RESONATE Study
Using an ad hoc analysis of data from the RESONATE study, changes in clinical staging (by Binet or Rai) can identify different response categories among patients evaluated by the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria, and may be a useful and cost-effective method to evaluate treatment response at different time points over the course of the disease. Using this approach, the superiority of ibrutinib over ofatumumab in heavily pretreated CLL patients was confirmed and further elucidated.
PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter’s Transformation: An Updated Report from a Phase 2 Trial (MC1485)
Pembrolizumab has an acceptable safety profile in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and Richter’s syndrome (RS) patients and substantial therapeutic activity in RS. However, single-agent pembrolizumab does not appear to have significant therapeutic activity in R/R CLL.
Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
An integrated safety analysis of treatment with single-agent ibrutinib for up to 5 years for patients with treatment-naïve or relapsed/refractory CLL/SLL revealed adverse events that were primarily grade 1/2 and were manageable with prolonged treatment.
Identification of Baseline Characteristics That Predict Good Outcome of alloHCT in Young CLL Patients - A Retrospective Analysis from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
The most important positive prognostic factor for 2-year nonrelapse mortality in chronic lymphocytic leukemia (CLL) patients following allogeneic hematopoietic stem-cell transplantation (alloSCT) is the donor HLA match. AlloSCT still remains a valid option for younger, high cytogenetic risk, refractory/relapsed CLL patients with an HLA-allele well-matched donor.
Preclinical Analyses Support Clinical Investigation of Combined Anti-CD19 CAR-T Cell, JCAR017 with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia
Ibrutinib enhances intrinsic JCAR017 activity and may improve outcomes in chronic lymphocytic leukemia patients treated with anti-CD19 CAR T therapy, irrespective of Bruton tyrosine kinase mutational status.
Long-Term Follow-Up of Chlorambucil plus Rituximab Combination as Frontline Therapy for Elderly and/or Unfit Patients with CLL, Including Risk Stratification
Treatment of elderly and/or unfit chronic lymphocytic leukemia (CLL) patients with chlorambucil plus rituximab is associated with low toxicity, a high overall response rate and durable progression-free survival, especially in patients with a mutated IGHV profile and not carrying del17p and del11q. In this low-risk subset of unfit patients, this combination could represent the optimal therapeutic option taking into consideration safety, efficacy, and cost.
Management and Outcomes of Atrial Fibrillation in Patients Receiving Ibrutinib for Hematologic Malignancies at a Single Center
Initial Results of a Multicenter, Phase II Study of Ibrutinib plus FCR (iFCR) as Frontline Therapy for Younger CLL Patients
Ibrutinib plus fludarabine/cyclophosphamide/rituximab (FCR) induces deep responses in previously untreated young patients with chronic lymphocytic leukemia (CLL), with 39% of evaluable patients achieving complete response with bone marrow minimal residual disease negativity (BM MRD-neg) and 89% achieving BM MRD-neg, significantly higher than the 20% rate seen historically with FCR alone.
11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies
In pooled data from 3 randomized studies, the benefit of ibrutinib on progression-free and overall survival is most marked in patients with CLL/SLL with del11q, which is not the case with ofatumumab, chlorambucil, or bendamustine/rituximab.
Page 8 of 10
Results 71 - 80 of 99
Results 71 - 80 of 99